OpenAI acquires Orchestra Bio, maker of AI agents for drug development

OpenAI has acquired Orchestra Bio, a startup building AI agents that help pharmaceutical companies manage drug development. The technology will be integrated into OpenAI's life sciences suite Rosalind. The deal value was not disclosed.

• Orchestra Bio builds AI agents for managing drug development
• Its tech will be folded into OpenAI's Rosalind life sciences suite
• Financial terms of the acquisition were not disclosed